A phase 2 study evaluated the efficacy and safety of adding pembrolizumab to trimodal therapy as a bladder-sparing approach for muscle-invasive bladder cancer (MIBC).
Breast02, led by a senior medical oncologist and researcher from the National Cancer Centre Singapore, has demonstrated a ...
Two inhibitors of the same immune checkpoint family produced high response rates and evidence of durability in preliminary ...
Revised trial procedures add intensified hematologic and cardiac monitoring to mitigate toxicities consistent with dual ...
Almost 60% of patients met the primary endpoint of progression-free survival (PFS) at 6 months with the CDK4/6 inhibitor ...
Early discontinuation of intravenous antibiotics regardless of neutrophil recovery reduced unnecessary antibiotic exposure without indications of compromised safety. Although the study was not powered ...
These data were simultaneously published in The Lancet: “ Overall survival with relacorilant and nab-paclitaxel in patients with platinum-resistant ovarian cancer (ROSELLA): a phase 3 randomised ...
Learn how G-CSF and trilaciclib help prevent febrile neutropenia in extensive-stage SCLC, with NCCN-backed timing tips and ...
In connection with the deal, Assertio has divested the rest of its assets to New Jersey generics and branded drugmaker ...
Macrogenics said the Food and Drug Administration has lifted its partial clinical hold on the oncology company's trial of a cancer treatment. The hold has been lifted for a Phase 2 study of ...
Lower rates of severe bone pain incidence seen for the 72-hour group vs 24- and 48-hour groups. HealthDay News — For patients with breast cancer, administration of pegfilgrastim 72 hours ...
Women given pegfilgrastim to prevent myelosuppression after chemotherapy for breast cancer often develop bone pain — but a small clinical trial suggests that delaying the drug by just one extra day ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results